



July 2011

**Apixaban (Eliquis<sup>®</sup>▼) for the prevention of venous thromboembolic events in adult patients who have undergone hip or knee replacement surgery**

The Interface Prescribing and New Therapies Subgroup (IPNTS) discussed the above drug at a meeting on the 27<sup>th</sup> July 2011. The recommendation of this subgroup is as follows:\*

The New Therapies Subgroup of the GMMMG considered the use of apixaban for the prevention of venous thromboembolic events in adult patients who have undergone hip or knee replacement surgery.

**The group recommends that apixaban may be considered as a treatment option for the above indication. Apixaban should be used in accordance with NICE Clinical Guideline 92 which makes recommendations on the prevention of VTE in a variety of patient populations, including those undergoing elective hip or knee replacement.**

Two out of three trials found apixaban to be superior to enoxaparin and apixaban and enoxaparin were found to be associated with comparable levels of all types of bleeding and other adverse effects (including serious adverse effects) were comparable.

This recommendation will be reviewed once apixaban has been launched and a price for the drug is available.

According to set criteria apixaban was deemed to be a low priority for funding

Review date: July 2013

\* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.